SOURCE: Streetwise Reports

Streetwise Reports

January 15, 2016 09:00 ET

Euro Pacific Canada's Doug Loe Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - January 15, 2016) -  The new year is off to a turbulent start, with indices across all markets, including biotech, sliding downward in the face of headwinds from China. Canadian healthcare stocks offer a windbreak for biotech investors, however, especially if they select a diversified basket across the various sectors. In this interview with The Life Sciences Report, Euro Pacific Canada's Doug Loe details a basket of Canadian companies that offer shelter from the storm.

Included in this interview is: Cipher Pharmaceuticals Inc. (NASDAQ: CPHR).

The Life Sciences Report: The landscape for pharmaceuticals was a bit rocky in the U.S. in 2015, particularly when it came to drug pricing. Did any of that volatility spill over into the Canadian biotech market?

Doug Loe: The sector is an eclectic one, with a multiplicity of publicly traded firms across all healthcare silos. These firms have generated strong returns in recent quarters, including even the specialty pharmaceutical sector, which has experienced some market value compression in Canada through corresponding valuation declines in two larger members of this category. Because our healthcare universe is so diverse, and thus largely devoid of any singular factors that drive valuations one way or the other, we see the sector as…

Continue reading this interview: A Bucket of Canadian Stocks Set to Soar in 2016: Euro Pacific Canada's Doug Loe

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.


Cipher Pharmaceuticals Inc. is a sponsor of Streetwise Reports. Douglas Loe had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Loe and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Contact Information